Amicus Therapeutics Inc News - FOLD

Professional-Grade Tools, for Individual Investors.

Premium

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that...

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that...

Form 8-K - Current report

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva

PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it...

Monksdream 2 months ago

FOLD under $15

👍️0

Monksdream 5 months ago

FOLD under $10

👍️0

TheFinalCD 1 year ago

https://twitter.com/StuckInStock/status/1707420486630588847

👍️0

Triple nickle 1 year ago

Should be 18.00 already

👍️0

georgie18 3 years ago

FOLD ...$9.47...out on the gap up from the $9 range buys...bidding the open gap...will enter again for another trade...:party:
[10:06 AM]
georgie18 — 05/24/2021
FOLD...back in at $9.02...:party:

👍️0

georgie18 4 years ago

FOLD...$9.24...in the P/M...:party:
[9:25 AM]
georgie18 — Yesterday at 9:41 AM
FOLD...$9.00...took a starter here...:party:

👍️0

georgie18 4 years ago

FOLD...$9.00...took a starter here...:party:

👍️0

Mygolfballs 4 years ago

How is this not being talkd about?

Ihub is only penny flippers?

Pffffft

👍️0

realfast95 4 years ago

Sanofi enzyme replacement therapy shows mixed results in Pompe study
Jun. 16, 2020 8:24 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor

Sanofi (NASDAQ:SNY) announces positive results from a Phase 3 clinical trial, COMET, evaluating avalglucosidase alfa, an enzyme replacement therapy, in patients with late-onset Pompe disease, an inherited disorder characterized by the buildup of glycogen in the body's cells due to the dysfunction of a certain enzyme.

The study met the primary endpoint demonstrating non-inferiority (no worse than) to alglucosidase alfa (Lumizyme) as measured by the change in respiratory function but it failed to demonstrate superiority, the other primary objective.

Since superiority was not shown, statistical testing of the secondary endpoints was not done.

The safety profiles were comparable.

Development is ongoing.

👍️0

realfast95 4 years ago

CONFIRMED breakout above 13.15, no resistance in area just above.
Type: True breakout from triple resistance.
Target: 14.32,

👍️0

realfast95 4 years ago

Jun-17-20 Initiated BTIG Research Buy $19

👍️0

realfast95 4 years ago

Amicus Therapeutics (FOLD) is seeing some action in the analyst community this week. Yesterday, both JP Morgan and H.C. Wainwright ($20 price target) reissued Buy ratings on this rare disease concern. Today, Citigroup does the same with $15 price target. Here is the commentary from Citi's analyst

The analyst attributes the weakness yesterday in shares of Amicus Therapeutics to Sanofi's (SNY) press release indicating that the company will release Phase 3 data for avalglucosidase alfa at a virtual science session on June 16. This is a key event for Amicus as this neoGAA would compete with its investigational drug AT-GAA, Bansal tells investors in a research note. Given the company issued a press release about hosting such an event, investors are likely putting a high probability to neoGAA's success, hence the weakness in Amicus shares, says the analyst. However, he sees enough differences between the respective Phase 3 programs that it is not easy to compare neoGAA data with AT-GAA on an apples to apples basis. Further, Amicus does not get much credit for AT-GAA in current valuation as fair value of the company is $10 per share on Galafold alone".

https://seekingalpha.com/instablog/498952-bret-jensen/5458158-biotech-analyst-run-down-for-tuesday

👍️0

Glider549 5 years ago

Amicus was able to achieve positive interim results from a phase 1/2 study using AAV-CLN6 gene therapy to treat patients with Batten disease.

Another gene therapy, known as AT-GAA, is currently being explored in a phase 3 study to treat patients with Pompe disease; enrollment completion is expected end of 2019.

The 6-month and 24-month data using AT-GAA to treat patients with Pompe disease are expected to be presented at the World Muscle Society October 1-5, 2019.

Amicus Therapeutics had $575.7 million in cash as of June 30, 2019, with enough cash to fund its operations into 2021.

👍️0

ClayTrader 5 years ago

* * $FOLD Video Chart 05-30-2019 * *

Link to Video - click here to watch the technical chart video

👍️0

ClayTrader 6 years ago

* * $FOLD Video Chart 03-01-2019 * *

Link to Video - click here to watch the technical chart video

👍️0

stock1ace1 7 years ago

Not looking so good on news ..

Study Did Not Meet Primary Endpoints

: (

👍️0

stocktrademan 7 years ago

FOLD buy 12.19

gapped up on FDA speeding up approval process for product
holding gains after recent 18.4M offering at $12.25

normal chart

log chart

👍️0

Inoviorulez 7 years ago

https://seekingalpha.com/article/4087015-amicus-nda-submission-proves-king-treating-fabry-disease

👍️0

trendmkr 8 years ago

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Could Be The Force That Brings Change To The FDA https://marketexclusive.com/77970-2/77970/?icd1

👍️0

ClayTrader 8 years ago

* * $FOLD Video Chart 03-01-17 * *

Link to Video - click here to watch the technical chart video

👍️0

DorseyE 8 years ago

Check this out
RDHL has1 NDA filling & 2 phase 3 results due by 6/30/2017 + 1 phase 2 due due by 7/31/2017///

👍️0

trendmkr 8 years ago

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Announces The Closure Of Its Senior Convertible Notes http://marketexclusive.com/amicus-therapeutics-inc-nasdaqfold-announces-closure-senior-convertible-notes/50881/?icd1

👍️0

ClayTrader 8 years ago

* * $FOLD Video Chart 12-15-16 * *

Link to Video - click here to watch the technical chart video

👍️0

stocktrademan 8 years ago

FOLD bearish 5.81

normal chart

log chart

👍️0

ClayTrader 8 years ago

* * $FOLD Video Chart 11-29-16 * *

Link to Video - click here to watch the technical chart video

👍️0

jones99 8 years ago

Rare opportunity to add on market overreaction. 10-15% discount is reasonable. 28-30% is easy money. Believe LT FOLD is a mega winner.

👍️0

thelittleguy 8 years ago

Well there is a huge short position that is feeling the pinch. I only hope that pinch keeps getting tighter and tighter. :)

👍️0

ClayTrader 8 years ago

* * $FOLD Video Chart 11-07-16 * *

Link to Video - click here to watch the technical chart video

👍️0

stocktrademan 8 years ago

FOLD bullish 7.02

nasdaq stocks $1-10 with volume > 100,000

👍️0

stocktrademan 8 years ago

FOLD bullish 6.7821

👍️0

stocktrademan 8 years ago

FOLD bullish 6.595

👍️0

thelittleguy 8 years ago

I agree. Are physicians going jump on board or take a wait and see approach? You never know until you start seeing the numbers come in. My fingers are crossed and my toes too.

👍️0

Rolling inflaton 8 years ago

I am! Waiting for revenues to start to come in from Europe. That alone can justify the current valuation, but might take a few quarters to get them rolling. Everything else is upside. Let's see what they say in the CC.

👍️0

thelittleguy 8 years ago

Is no one invested in FOLD but me? Where is everyone?

👍️0

ClayTrader 8 years ago

* * $FOLD Video Chart 07-27-16 * *

Link to Video - click here to watch the technical chart video

👍️0

stocktrademan 8 years ago

FOLD bearish 5.87

👍️0

saziz 9 years ago

$FOLD Detailed setup : http://www.upstockstrading.com/2015/12/upstockstrading-daily-newsletter-26/ should be heading back to $11

👍️0

Kylef 9 years ago

Did u Stay in that one for today?

check these out -Add to Watchlist: Apdn,nesv,mine,fzro,awgi from 0.0115, psid from 0.0197, nhmd,rovi, orig from 1.68, kgc

👍️0

Pennybuster 9 years ago

Sold 75% Plus 1.75. Still Looks Like More Upside Coming Imo.

👍️0

Pepperchino 9 years ago

I am with you on this call...

👍️0

Kylef 9 years ago

I believe this is The beginning of an uptrend.

👍️0

Pennybuster 9 years ago

$FOLD Nice Bounce Here The Past Few Sessions.

👍️0

Pennybuster 9 years ago

$FOLD. Great Day Today! Finally The Bounce We Were Looking For.

👍️0

Pennybuster 9 years ago

$FOLD Still Searching 4 It's Bottom. Added More Today At 6.00.

👍️0

blindjohn 9 years ago

Gonna bounce at open tomorrow imo

👍️0

perfectpicksfor -you 9 years ago

Back in at close to the low of the day ,Will we see green again today.

girlfriend 9 years ago

FOLD is not dead money to me…..trade it.

👍️0

sorkin 9 years ago

I see a bounce pre market. Fake head, will stay away. $FOLD is dead money at this point.

👍️0

OB_WEALTH_INC 9 years ago

SHORTS GOT SQUEEZED @ 9.30 LOL

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amicus Therapeutics Inc (FOLD)

Professional-Grade Tools, for Individual Investors.

FOLD News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

Form 8-K - Current report

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva

FOLD Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amicus Therapeutics Inc (FOLD) News

Amicus Therapeutics Inc (FOLD)

Professional-Grade Tools, for Individual Investors.

FOLD News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

Form 8-K - Current report

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva

FOLD Discussion

Your Recent History

Company

Business

Popular

Get The App